ACURX PHARMACEUT. DL-001
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more
Market Cap & Net Worth: ACURX PHARMACEUT. DL-001 (3ZO)
ACURX PHARMACEUT. DL-001 (F:3ZO) has a market capitalization of $7.74 Million (€7.54 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #37976 globally and #5020 in its home market, demonstrating a 1331.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ACURX PHARMACEUT. DL-001's stock price €5.09 by its total outstanding shares 1481350 (1.48 Million).
ACURX PHARMACEUT. DL-001 Market Cap History: 2021 to 2025
ACURX PHARMACEUT. DL-001's market capitalization history from 2021 to 2025. Data shows growth from $6.02 Million to $7.74 Million (0.63% CAGR).
ACURX PHARMACEUT. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ACURX PHARMACEUT. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 3ZO by Market Capitalization
Companies near ACURX PHARMACEUT. DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to ACURX PHARMACEUT. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ACURX PHARMACEUT. DL-001 Historical Marketcap From 2021 to 2025
Between 2021 and today, ACURX PHARMACEUT. DL-001's market cap moved from $6.02 Million to $ 7.74 Million, with a yearly change of 0.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €7.74 Million | +522.25% |
| 2024 | €1.24 Million | -76.49% |
| 2023 | €5.29 Million | -4.92% |
| 2022 | €5.57 Million | -7.58% |
| 2021 | €6.02 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ACURX PHARMACEUT. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.74 Million USD |
| MoneyControl | $7.74 Million USD |
| MarketWatch | $7.74 Million USD |
| marketcap.company | $7.74 Million USD |
| Reuters | $7.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.